PATENT CLAIM ANALYSIS

Application Number: 16123072
Application Type: Utility
Filing Date: 2018-09
Publication Date: 2019-01
Patent Classification: ["544", "310000"]

Abstract:
The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D1-mediated (or D1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD, PD, or pharmacotherapy therapy), and Parkinson's disease.

Claim (Index 14):
The method of  claim 2  wherein R 3  is H; and R 4  is H, halogen, or methyl, wherein the methyl is optionally substituted with 1, 2, or 3 substituents each independently selected from the group consisting of halogen, \u2014OH, and C 1-4  alkoxy.

Metadata:
- Claim Count in Document: 50.0
- Percentile: 97.0
- Lexical Diversity: 1.68519
- Patent Class: 544.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14311963', '15729111', '15349075', '14819541', '14339123']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8257898659710705
- 35 USC 102 Novelty (BERT): 0.5811866234437385
- Combined Prediction Score: 0.8013295417183373
- Mean Citation Score: 447.258236
- Max Citation Score: 471.30627
- Similarity Product: 455.5926487532008

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test